MindMaze Therapeutics

We are proud to share MindMaze Therapeutics has been selected as one of the World’sTop #HealthTech companies of 2026 by TIME. This recognition is testament to our mission of providing #scalable precision #neurotherapeutics for patients wherever they may happen to be, from the hospital to the home.

Today we announced the upcoming launch of MindMotion Lite, a tablet based version of our clinically proven MindMotion platform, purpose built for home deployment. This represents a critical inflection point for MindMaze Therapeutics as it accelerates our commercial expansion by making neurorehabilitation accessible to everyone who needs care, regardless of where they are via an easy to deploy, scalable form factor. We are in the process of onboarding launch partners so let us know if you'd like an in person or virtual demo.

We’re heading to Munich for the Baader Bank AG Investment Conference next week. MindMaze Therapeutics (SIX: MMTX) looks forward to meeting investors and discussing our strategy to expand global access to neurorehabilitation—from hospital to home. #Munich #Germany Monday, September 21, 2026 Company presentation: 17:40 Our CEO, Zach Henderson, and CFO, Jeremy Meinen, will also be available for one-on-one meetings. Attending the conference? Contact ir@mindmazetherapeutics.com to arrange a meeting. #BaaderInvestmentConference #MindMazeTherapeutics #InvestorRelations

High-quality rehab shouldn't be limited to urban centers. The technology, reimbursement pathways, and distribution networks to change that already exist. Now it's about getting them to every patient who needs them.

Real-world validation at scale is rare in neurology. In a two-year study with Vibra Healthcare presented at ASNR, MindMaze Therapeutics patients demonstrated statistically significant improvements in mobility and self-care across multiple U.S. sites. This is what the new standard of care looks like.

Our CEO, Zach Henderson, sharing insights on why MindMaze Therapeutics chose The Pearl CLT and Connect Labs by Wexford for its US headquarters. #Charlotte is rapidly becoming a leading MedTech hub.

Reactive care means waiting weeks for the next scheduled visit. For stroke and Parkinson's patients, that wait can make all the difference. We give care teams a real-time picture of every patient, every day, so they can act faster.

Appreciate the mention Jay White and the Realize Charlotte team for featuring us on Instagram recently! We love what you do for the Queen City community and are proud to be a part of the growing #clt #healthtech scene.

We are pleased to announce that Dr. John Krakauer has rejoined MindMaze Therapeutics as a strategic advisor. As John shared, "The clinical case for high-dose, high-intensity neurorehabilitation is now unambiguous: the brain is a learning organ, and recovery depends on delivering the right dose and intensity of training. Health systems have historically struggled to do so, lacking a scalable platform that could deliver it reliably across every care setting, including the home. MindMaze Therapeutics has spent years turning that science into a platform clinicians can actually deploy across the care continuum, while confirming in the real world what the science always suggested: dose and intensity drive recovery. This advisory role lets me stay closely engaged in that mission while pushing the underlying research forward."

Thanks to futurezone.at TECHNOLOGY NEWS for covering MindMaze Therapeutics in a recent story. Our mission is to help serve all patients facing neurological challenges by providing access to innovative, proven treatments, importantly at scale.